About Enzymotec (NASDAQ:ENZY)
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.
Industry, Sector and Symbol
Industry Commodity Chemicals
Trailing P/E Ratio-43.8888888888889
Forward P/E Ratio237.00
Sales & Book Value
Annual Sales$47.70 million
Price / Sales5.82
Cash Flow$0.06 per share
Price / Cash209.80
Book Value$6.00 per share
Price / Book1.98
Return on Equity1.24%
Return on Assets0.84%
Enzymotec (NASDAQ:ENZY) Frequently Asked Questions
What is Enzymotec's stock symbol?
Enzymotec trades on the NASDAQ under the ticker symbol "ENZY."
How were Enzymotec's earnings last quarter?
Enzymotec Ltd (NASDAQ:ENZY) released its earnings results on Wednesday, May, 17th. The biotechnology company reported $0.03 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.06 by $0.03. The biotechnology company had revenue of $12 million for the quarter, compared to analyst estimates of $14.23 million. Enzymotec had a return on equity of 1.24% and a net margin of 2.32%. The firm's revenue was down 14.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.09 EPS. View Enzymotec's Earnings History.
Where is Enzymotec's stock going? Where will Enzymotec's stock price be in 2018?
2 brokerages have issued 12-month price objectives for Enzymotec's shares. Their predictions range from $11.50 to $12.00. On average, they anticipate Enzymotec's stock price to reach $11.75 in the next year. View Analyst Ratings for Enzymotec.
What are Wall Street analysts saying about Enzymotec stock?
Here are some recent quotes from research analysts about Enzymotec stock:
- 1. According to Zacks Investment Research, "Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. " (10/17/2017)
- 2. Jefferies Group LLC analysts commented, "Enzymotec has been pressured by a shifting regulatory environment and lackluster demand even as it has accelerated investment in Vaya. Regulatory changes will continue to ripple through the supply chain in 2H17-2018. We expect shares to remain range-bound absent an improvement in end markets and sustained profitability in Vaya. Clarity around strategic opportunities in InFat and the pending CEO transition would help reduce its risk profile." (2/23/2017)
Who are some of Enzymotec's key competitors?
Some companies that are related to Enzymotec include Ciner Resources (CINR), Major Drilling Group Int'l (MDI), Athabasca Oil (ATH), Haynes International (HAYN), Uranium Participation (U), Senex Energy (SXY), Pengrowth Energy (PGF), Dundee Precious Metals (DPM), goeasy (GSY), Dorchester Minerals (DMLP), Intrepid Potash (IPI), Taseko Mines (TKO), Golden Star Resources (GSC), Trinidad Drilling (TDG), Highland Gold Mining (HGM), Sherritt International (S), Cardinal Energy (CJ) and Mount Gibson Iron (MGX).
Who are Enzymotec's key executives?
Enzymotec's management team includes the folowing people:
- Steve Dubin, Independent Chairman of the Board (Age 60)
- Erez Israeli, President, Chief Executive Officer (Age 48)
- Yoav Doppelt, Independent Vice Chairman of the Board (Age 48)
- Dror Israel, Chief Financial Officer, Vice President (Age 46)
- Yoav Kahane, Chairman of Advanced Lipids AB (Age 42)
- Yoni Twito, Chief Operating Officer (Age 47)
- Naama Zamir, Vice President - Human Resources and Information Systems (Age 43)
- Gai Ben-Dror, Vice President - Process Development (Age 45)
- Tzafra Cohen, Vice President - Research & Development (Age 47)
- Tamar D. Howson, Director (Age 68)
Who owns Enzymotec stock?
Enzymotec's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Delek Group Ltd. (8.54%), Renaissance Technologies LLC (2.74%), Gabelli Funds LLC (2.46%), Water Island Capital LLC (1.71%), GABELLI & Co INVESTMENT ADVISERS INC. (0.82%) and Highland Capital Management LP (0.46%). View Institutional Ownership Trends for Enzymotec.
Who bought Enzymotec stock? Who is buying Enzymotec stock?
Enzymotec's stock was acquired by a variety of institutional investors in the last quarter, including Delek Group Ltd., Gabelli Funds LLC, Water Island Capital LLC, Renaissance Technologies LLC, GABELLI & Co INVESTMENT ADVISERS INC., Highland Capital Management LP, Deutsche Bank AG and Paloma Partners Management Co. View Insider Buying and Selling for Enzymotec.
How do I buy Enzymotec stock?
Shares of Enzymotec can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enzymotec's stock price today?
One share of Enzymotec stock can currently be purchased for approximately $11.85.
How big of a company is Enzymotec?
Enzymotec has a market capitalization of $277.62 million and generates $47.70 million in revenue each year. The biotechnology company earns $-2,920,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Enzymotec employs 205 workers across the globe.
How can I contact Enzymotec?
Enzymotec's mailing address is Sagi 2000 Industrial Park, P.O. Box 6, MIGDAL HAEMEQ, 23106, Israel. The biotechnology company can be reached via phone at +972-7-47177177 or via email at [email protected]
MarketBeat Community Rating for Enzymotec (ENZY)MarketBeat's community ratings are surveys of what our community members think about Enzymotec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Enzymotec (NASDAQ:ENZY) Earnings History and Estimates Chart
Enzymotec (NASDAQ ENZY) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/15/2017||Q3 2017||$0.07||$0.04||$14.36 million||$13.67 million||View||N/A|
|8/16/2017||6/30/2017||$0.05||($0.10)||$12.78 million||$13.00 million||View||N/A|
|5/17/2017||3/31/2017||$0.06||$0.03||$14.23 million||$12.00 million||View||N/A|
|2/22/2017||Q416||$0.03||($0.10)||$11.47 million||$10.60 million||View||N/A|
|11/16/2016||Q316||$0.07||$0.03||$13.29 million||$11.40 million||View||N/A|
|8/9/2016||Q216||$0.08||$0.04||$14.90 million||$15.00 million||View||N/A|
|5/19/2016||Q116||$0.05||$0.09||$13.85 million||$14.00 million||View||Listen|
|2/17/2016||Q415||$0.10||$0.07||$14.01 million||$13.30 million||View||Listen|
|11/11/2015||Q315||$0.07||$0.08||$14.21 million||$12.40 million||View||Listen|
|8/12/2015||Q215||$0.06||$0.11||$12.39 million||$13.40 million||View||Listen|
|5/7/2015||Q115||$0.06||$0.09||$12.10 million||$12.25 million||View||N/A|
|2/18/2015||Q414||$0.08||$0.06||$11.11 million||$10.80 million||View||N/A|
|11/13/2014||Q314||$0.04||$0.05||$10.22 million||$9.50 million||View||N/A|
|8/5/2014||Q214||$0.10||$0.02||$14.88 million||$11.50 million||View||N/A|
|5/14/2014||Q114||$0.17||$0.24||$19.40 million||$23.70 million||View||N/A|
|2/13/2014||Q413||$0.11||$0.15||$11.64 million||$18.51 million||View||N/A|
|11/11/2013||Q313||$0.11||$0.13||$13.10 million||$22.50 million||View||Listen|
Enzymotec (NASDAQ:ENZY) Earnings Estimates
Current Year EPS Consensus Estimate: $0.05 EPS
Next Year EPS Consensus Estimate: $0.31 EPS
Dividend History for Enzymotec (NASDAQ:ENZY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Enzymotec (NASDAQ ENZY)
No insider trades for this company have been tracked by MarketBeat.com
Enzymotec (NASDAQ ENZY) News Headlines
Enzymotec (NASDAQ:ENZY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Enzymotec (NASDAQ:ENZY) Income Statement, Balance Sheet and Cash Flow Statement
Enzymotec (NASDAQ ENZY) Stock Chart for Wednesday, February, 21, 2018